Ligand id: 7985

Name: durvalumab

Compound class Antibody
Approved drug? Yes (FDA (2017), EMA (2018))
International Nonproprietary Names
INN number INN
10010 durvalumab
anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736
Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [2], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [1].
Database Links
Specialist databases
IMGT/mAb-DB 528
Other databases
GtoPdb PubChem SID 249565666
Search PubMed clinical trials durvalumab
Search PubMed titles durvalumab
Search PubMed titles/abstracts durvalumab
Wikipedia Durvalumab